`Date: April 23, 2014
`
`Filed on behalf of: NOVARTIS and LTS
`
`By: Raymond R. Mandra
`rmandra@fchs.com
`(212) 218-2100
`
`Nicholas N. Kallas
`nkallas@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS, INC.
`Petitioner,
`v.
`NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners.
`
`Case IPR2014-00549
`U.S. Patent No. 6,316,023
`
`PATENT OWNERS’
`MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(2)
`
`
`
`1. Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1)
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned
`
`states that Novartis AG (“Novartis”) and LTS Lohmann Therapie-Systeme AG
`
`(formerly LTS Lohmann Therapie-Systeme GmbH Co. KG) (“LTS”) are the Patent
`
`Owners and real parties-in-interest in IPR2014-00549 directed to U.S. Patent No.
`
`6,316,023 (“the ‘023 Patent”).
`
`2. Related Matters Pursuant to 37 C.F.R. § 42.8(b)(2)
`
`The ’023 Patent is being asserted in the following patent infringement
`
`lawsuits: (1) Novartis Pharm. Corp. et al. v. Par Pharm. Inc. et al., 1:11-cv-01077
`
`(D. Del.); (2) Novartis Pharm. Corp. et al. v. Watson Labs. Inc. et al., No. 1:11-cv-
`
`01112 (D. Del.); (3) Novartis Pharm. Corp. et al. v. Alvogen Pine Brook Inc. et al.,
`
`1:13-cv-00052 (D. Del.); (4) Novartis Pharm. Corp. et al. v. Alvogen Pine Brook
`
`Inc. et al., 1:13-cv-00370 (D. Del.); (5) Novartis Pharm. Corp. et al. v. Actavis,
`
`Inc. et al., No. 1:13-cv-00371 (D. Del.); (6) Novartis Pharm. Corp. et al. v. Noven
`
`Pharm. Inc., 1:13-cv-00527 (D. Del.); and (7) Novartis Pharm. Corp. et al. v.
`
`Noven Pharm. Inc., 1:14-cv-00111 (D. Del.).
`
`3. Identification of Lead and Back-Up Counsel
`Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10
`
`Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis and LTS designate
`
`Raymond R. Mandra (Reg. No. 34,382) as lead counsel and Nicholas N. Kallas
`
`(Reg. No. 31,530) as back-up counsel.
`
`-2-
`
`
`
`A power of attorney from each Patent Owner is being submitted with this
`
`Notice.
`
`4. Service Information Pursuant to 37 C.F.R. § 42.8(b)(4)
`
`Novartis and LTS may be served electronically using the following email
`
`address:
`
`ExelonPatchIPR@fchs.com
`
`Novartis and LTS may be served by postal mailing, hand-delivery, telephone
`
`or facsimile as follows:
`
`Raymond R. Mandra
`Fitzpatrick Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104
`Telephone: (212) 218-2100
`Facsimile:
`(212) 218-2200
`
`Dated: April 23, 2014
`
`Respectfully submitted,
`
`/Raymond R. Mandra/
`Raymond R. Mandra (Reg. No. 34,382)
`Lead Counsel for Patent Owner
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. (212) 218-2100
`Fax. (212) 218-2200
`rmandra@fchs.com
`
`-3-
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS, INC.
`Petitioner,
`v.
`NOVARTIS AG and LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners.
`
`Case IPR2014-00549
`U.S. Patent No. 6,316,023
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that Novartis AG And LTS Lohmann Therapie-
`
`Systeme AG’s Mandatory Notices under 37 C.F.R. § 42.8(a)(2) in connection with
`
`IPR2014-00549 were served on this 23rd day of April 2014 using electronic mail,
`
`sent to the following email addresses:
`
`Steven J. Lee (slee@kenyon.com); and
`Cynthia Lambert Hardman (chardman@kenyon.com).
`
`/Raymond R. Mandra/
`
`